India, June 1 -- Eli Lilly and Company (LLY) continued its deal-making momentum on June 1, 2026, announcing two new licensing agreements in Asia while also highlighting three infectious-disease acquisitions completed last week.
Lilly signed a licensing and research collaboration with Haisco Pharmaceutical Group, under which Lilly gained exclusive worldwide rights to select programs while Haisco retains rights in China and certain territories.
As per the terms of the agreement, Lilly will make $87 million in upfront and near-term payments, with the deal also providing for up to $2.97 billion in potential milestone payments and tiered royalties.
The other deal signed by Lilly today is a global licensing deal with Hanmi Pharmaceutical (excl...